東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Novel Traditional Chinese Medicine-P...

Guan, Huaji.

Linked to FindBook

Google Book

Amazon

博客來

Novel Traditional Chinese Medicine-Platinum Compound that Bypasses Mitotic DNA Damage Checkpoints in Cancer Cells.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Novel Traditional Chinese Medicine-Platinum Compound that Bypasses Mitotic DNA Damage Checkpoints in Cancer Cells./
Author:	Guan, Huaji.
Description:	257 p.
Notes:	Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 2053.
Contained By:	Dissertation Abstracts International72-04B.
Subject:	Health Sciences, Pharmacology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3445954
ISBN:	9781124494234

Novel Traditional Chinese Medicine-Platinum Compound that Bypasses Mitotic DNA Damage Checkpoints in Cancer Cells.
Guan, Huaji.

Novel Traditional Chinese Medicine-Platinum Compound that Bypasses Mitotic DNA Damage Checkpoints in Cancer Cells. - 257 p.

Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 2053.

Thesis (Ph.D.)--The Chinese University of Hong Kong (Hong Kong), 2010.

Background: A common procedure in current cancer chemotherapy is to induce genomic stress in cancer cells, leading to irreparable DNA damage and eventually cell death. However, there are several DNA repair mechanisms in cancer cells to maintain genomic stability, which require cell cycle checkpoints to stop cell proliferation for DNA damage repair, thereby avoiding errors in cellular events like DNA replication, transcription and mitosis. Among these cell cycle checkpoints, antephase and G2 checkpoints are two gate checkpoints for mitosis. Abrogation of G2 checkpoint has been reported to give rise to synergistic cytotoxic effect with DNA damaging agents, representing a means of circumventing drug resistance in chemotherapy.

ISBN: 9781124494234Subjects--Topical Terms:

1017717
Health Sciences, Pharmacology.

Novel Traditional Chinese Medicine-Platinum Compound that Bypasses Mitotic DNA Damage Checkpoints in Cancer Cells.
LDR:04896nam 2200337 4500 001 1402788
005 20111103090535.5
008 130515s2010 ||||||||||||||||| ||eng d
020 $a 9781124494234
035 $a (UMI)AAI3445954
035 $a AAI3445954
040 $a UMI $c UMI
100 1 $a Guan, Huaji. $3 1682004
245 1 0 $a Novel Traditional Chinese Medicine-Platinum Compound that Bypasses Mitotic DNA Damage Checkpoints in Cancer Cells.
300 $a 257 p.
500 $a Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 2053.
500 $a Adviser: Vincent Hon Leung Lee.
502 $a Thesis (Ph.D.)--The Chinese University of Hong Kong (Hong Kong), 2010.
520 $a Background: A common procedure in current cancer chemotherapy is to induce genomic stress in cancer cells, leading to irreparable DNA damage and eventually cell death. However, there are several DNA repair mechanisms in cancer cells to maintain genomic stability, which require cell cycle checkpoints to stop cell proliferation for DNA damage repair, thereby avoiding errors in cellular events like DNA replication, transcription and mitosis. Among these cell cycle checkpoints, antephase and G2 checkpoints are two gate checkpoints for mitosis. Abrogation of G2 checkpoint has been reported to give rise to synergistic cytotoxic effect with DNA damaging agents, representing a means of circumventing drug resistance in chemotherapy.
520 $a Aim: Cisplatin is the first platinum drug that shows promising anti-tumor effect clinically. Oxaliplatin, a third-generation platinum drug that incorporates a diaminocyclohexane (DACH) structural entity, can overcome cisplatin resistance. R,R-5, a novel platinum compound that integrates the DACH entity with a demethylcantharidin (DMC) component that is derived from a traditional Chinese medicine (TCM), can also overcome cisplatin resistance. The principal objectives of this study was to investigate in detail, the effect of these compounds at the antephase and G2 checkpoints of the cell cycle, and to establish the relationship (if any) between different structural entities with checkpoint activation. The ultimate aim of the study was to ascertain the potential for the development of novel checkpoint abrogators as anti-tumor agents.
520 $a Methods: Microarray analysis was used to detect gene transcription profiles after drug treatments. The activation of mitotic checkpoints was inspected by counting mitotic cells and utilizing flow cytometry. Using Western blotting, the activation of certain key players in the antephase and G2 checkpoint was revealed. MTT assays were performed to show the outcome of checkpoint activation.
520 $a Results: In HCT116 cells, 35 genes that facilitate G2/M transition were found to be up-regulated after R,R-5 treatment compared with oxaliplatin in the microarray analysis, implying the bypass of mitotic checkpoints by R,R-5 rather than oxaliplatin. Acute stress (2 hour) of cisplatin activated the antephase checkpoint, resulting in a rapid decrease in mitotic index and phosphorylation of histone H1, which avoided mitotic catastrophe and promoted cell survival in HeLa cells. Further experiments demonstrated that this antephase checkpoint could be abrogated by c-Abl and p38MAPK inhibitors, or siRNAs against c-Abl or MEKK1, suggesting that this checkpoint may be controlled by an MMR/c-Abl/MEKK1/p38MAPK pathway. In contrast, oxaliplatin and R,R-5 did not activate this antephase checkpoint. Moreover, after 24 hour oxaliplatin treatment in HeLa cells, the mitotic index and CDK1 activity were decreased, which could be restored by concomitant treatment with ATM/ATR inhibitor and DMC. This indicated the activation of G2 checkpoint by oxaliplatin and implied that DMC can abrogate oxaliplatin-activated G2 checkpoint by restoring CDK1 activity. Cisplatin could also activate G2 checkpoint, whereas R,R-5 apparently bypassed this G2 checkpoint.
520 $a Conclusions: Acute stress to cisplatin can activate the MMR/c-Abl/MEKK1/p38MAPK pathway, leading to the activation of antephase checkpoint, and stop cells from entering mitosis immediately. DACH-containing platinum compound oxaliplatin fails to activate this antephase checkpoint. However, both cisplatin and oxaliplatin can activate the G2 checkpoint, which can be abrogated by DMC. In contrast, RR-5 can bypass both the antephase and G2 checkpoints. In summary, novel TCM-platinum compound R,R-5 can bypass mitotic DNA damage checkpoints in cancer cells and thus has the potential for further development as an anti-cancer drug.
590 $a School code: 1307.
650 4 $a Health Sciences, Pharmacology. $3 1017717
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0419
690 $a 0572
690 $a 0992
710 2 $a The Chinese University of Hong Kong (Hong Kong). $3 1017547
773 0 $t Dissertation Abstracts International $g 72-04B.
790 1 0 $a Lee, Vincent Hon Leung, $e advisor
790 $a 1307
791 $a Ph.D.
792 $a 2010
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3445954